Guía de Práctica Clínica sobre Diabetes Mellitus Tipo 1.

V. resumida | Info pacientes | Consulta rápida

  1. Introducción
  2. Alcance y objetivos
  3. Metodología de la guía
  4. Definición y criterios diagnósticos de la diabetes mellitus tipo 1
  5. Educación diabetológica
  6. Alimentación
  7. Ejercicio físico
  8. Control glucémico
  9. Manejo de la diabetes mellitus tipo 1 en situaciones especiales
  10. Complicaciones agudas
  11. Complicaciones crónicas
  12. Organización de consulta
  13. Difusión e implementación
  14. Líneas de investigación futuras
  15. Anexos
  16. Listado completo de tablas y figuras
  17. Bibliografía

Abre nueva ventana: Apartado xx en versión pdf
Descargar GPC sobre Diabetes Mellitus (3,35 Mb)

Bibliografía

  1. 1. Scottish Intercollegiate Guidelines Network. A guideline developers’ handbook. Edinburgh: Scottish Intercollegiate Guidelines Network 2008;Sign 50.
  2. 2. Instituto Aragonés de Ciencias de la Salud-I+CS. Grupo de trabajo sobre GPC. Elaboración de Guías de Práctica Clínica en el Sistema Nacional de Salud. Manual Metodológico. Madrid: Plan Nacional para el SNS del MSC. Guías de Práctica Clínica en el SNS: I+CS Nº 2006/01 2007.
  3. 3. National Institute for Health and Clinical Excellence (January 2009). The guidelines manual. London: national Institute for Health and Clinical Excellence. Available from: www.nice.org.uk.
  4. 4. Soriguer F, Goday A, Bosch-Comas A, Bordiú E, Calle A, Carmena R, et al. Prevalence of diabetes mellitus and impaired glucose regulation in Spain. Diabetes Study Diabetología (Journal of the European Association for the Study of Diabetes) (EASD) en prensa 2010.
  5. 5. Estrategia en diabetes del Sistema Nacional de Salud. Ministerio de Sanidad y Consumo. Agencia Española del Medicamento y Productos Sanitarios Madrid 2007.
  6. 6. Etxeberria A, Rotaeche R, Lekue I, Callén B, Merino M, Villar Mea. Descripción de la metodología de elaboración-adaptación-actualización empleada en la guía de práctica clínica sobre asma de la CAPV. Proyecto de Investigación Comisionada Vitoria-Gasteiz Departamento de Sanidad Gobierno Vasco 2005 Informe nº: Osteba D-05-03 2005
  7. 7. National Institute for Health and Clinical Excellence. Diagnosis and management of type 1 diabetes in children, young people and adults. Clinical Guideline 15 2004 Jul.
  8. 8. ADAPTE.Manual for Guideline Adaptation. Version 1. 0. ADAPTE Collaboration 2007.
  9. 9. NICE. Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus. NICE technology appraisal guidance 151. Review of technology appraisal guidance 57 2008.
  10. 10. The AGREE Collaboration. Appraisal of Guidelines for Research & Evaluation (AGREE). www agreecollaboration org 2001 Sep.
  11. 11. Scottish Intercollegiate Guidelines Network. Management of diabetes. A national clinical guideline. SIGN Publication 2001;Nº 55.
  12. 12. Oxford. Levels of Evidence and Grades of Recommendation. Oxford Centre for Evidencebased Medicine [sitio web] 2001.
  13. 13. Schmidt KD, Valeri C, Leslie RD. Autoantibodies in Type 1 diabetes. Clin Chim Acta 2005 Apr;354(1-2):35-40.
  14. 14. Leslie D, Lipsky P, Notkins AL. Autoantibodies as predictors of disease. J Clin Invest 2001 Nov;108(10):1417-22.
  15. 15. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications. Report of a WHO consultation. Part I: Diagnosis and classification of diabetes mellitus. Geneva WHO 1999.
  16. 16. International Society for Pediatric and Adolescent Diabetes (ISPAD). Consensus guidelines 2000. ISPAD consensus guidelines for the management of type 1 diabetes mellitus in children and adolescents. Zeist: Medical Forum International 2000.
  17. 17. Bingley PJ. Clinical applications of Diabetes antibody testing. J Clin Endocrinol Metab 2010;95:25-33.
  18. 18. Turner R, Stratton I, Horton V, Manley S, Zimmet P, Mackay IR, et al. UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. UK Prospective Diabetes Study Group. Lancet 1997 Nov 1;350(9087):1288-93.
  19. 19. Bober E, Dundar B, Buyukgebiz A. Partial remission phase and metabolic control in type 1 diabetes mellitus in children and adolescents. J Pediatr Endocrinol Metab 2001;14:435-41.
  20. 20. Heinze E, Thon A. Honeymoon period in insulin-dependent diabetes mellitus. Pediatrician 1985;12:208-12.
  21. 21. Muhammad BJ, Swift PG, Raymond NT, Botha JL. Partial remission phase of diabetes in children younger than age 10 years. Arch Dis Child 1999 Apr;80(4):367-9.
  22. 22. Bonfati R, Bazzigaluppi E, Calori G, Riva MC, Viscardi M, Bognetti E, et al. Parameters associated with residual insulin secretion during the first year of disease in children and adolescents with Type 1 diabetes mellitus. Diabet Med 1998;15:844-50.
  23. 23. Lombardo F, Valenzise M, WasniewsCAD M, Messina MF, Ruggeri C, Arrigo T, et al. Twoyear prospective evaluation of the factors affecting honeymoon frequency and duration in children with insulin dependent diabetes mellitus: The key-role of at diagnosis. Diabetes Nutr Metab 2002;15:246-51.
  24. 24. Bonfanti R, Bazzigaluppi E, Calori G, Riva MC, Viscardi M, Bognetti E, et al. Parameters associated with residual insulin secretion during the first year of disease in children and adolescents with Type 1 diabetes mellitus. Diabet Med 1998 Oct;15(10):844-50.
  25. 25. Knip M, PuukCAD R, CADar ML, Akerblom HK. Remission phase, endogenous insulin secretion and metabolic control in diabetic children. Acta Diabetol Lat 1982;19:243-51.
  26. 26. Standards of medical care in diabetes—2010. Diabetes Care 2010 Jan;33 Suppl 1:S11-S61.
  27. 27. Weedon MN, Frayling TM. Insights on pathogenesis of type 2 diabetes from MODY genetics. Curr Diab Rep 2007;7(2):131-8.
  28. 28. Raeder H, Johansson S, Holm PI, Haldorsen IS, Mas E, Sbarra V, et al. Mutations in the CEL VNTR cause a syndrome of diabetes and pancreatic exocrine dysfunction. Nature Genetics 2006 Jan;54-62.
  29. 29. Estalella I, Rica I, Perez DN, Bilabo JR, Vazquez JA, San Pedro JI, et al. Mutations in GCK and HNF-1alpha explain the majority of cases with clinical diagnosis of MODY in Spain. Clin Endocrinol 2007;67(4):538-46.
  30. 30. Costa A, Bescos M, Velho G, Chevre J, Vidal J, Sesmilo G, et al. Genetic and clinical characterisation of maturity-onset diabetes of the young in Spanish families. Eur J Endocrinol 2000;142(4):380-6.
  31. 31. Barrio R, Bellanne-Chantelot C, Moreno JC, Morel V, Calle H, Alonso M, et al. Nine novel mutations in maturity-onset diabetes of the young (MODY) candidate genes in 22 Spanish families. J Clin Endocrinol Metab 2002;87(6):2532-9.
  32. 32. Ellard S, Bellanné-Chantelot C, Hattersley AT. European Molecular Genetics Quality Network (EMQN) MODY group. Best practice guidelines for the molecular genetic diagnosis of maturity- onset diabetes of the young. Diabetol 2008;51:546-53.
  33. 33. Barker JM. Clinical review: Type 1 diabetes-associated autoimmunity: natural history, genetic associations, and screening. J Clin Endocrinol Metab 2006 Apr;91(4):1210-7.
  34. 34. Kordonouri O, Maguire AM, Knip M, Schober E, Lorini R, Holl RW, et al. ISPAD Clinical Practice Consensus Guidelines 2006-2007. Other complications and associated conditions. Pediatr Diabetes 2007;8:171-6.
  35. 35. De Graaff LCG, Smit JWA, Radder JK. Prevalence and clinical significance of organ-specific autoantibodies in type 1 diabetes mellitus. Net J Med 2007;65(7):235-47.
  36. 36. Fröhlich-Reiterer EE, Hofer S, Kaspers S, Herbst A, Kordonouri O, Schwarz H-P, et al. Screening frequency for celiac disease and autoimmune thyroiditis in children and adolescents with type 1 diabetes mellitus-data from a German/Austrian multicentre survey. Pediatr Diabetes 2008;9:546-53.
  37. 37. Nóvoa Y, López-Capapé M, Lara E, Alonso M, camarero C, Barrio R. Impacto del diagnóstico de la enfermedad celíaca en el control metabólico de la diabetes tipo 1. An Pediatr (Barc) 2008;68(1):13-7.
  38. 38. Poulain C, Johanet C, Delcroix C, Lévy-Marchal C, Tubiana-Rufi N. Prevalence and clinical features of celiac disease in 950 children with type 1 diabetes in France. Diabetes Metab 33 2007;453-8.
  39. 39. Larsson K, Carlsson A, Cederwall E, Jönsson B, Neiderud J, Jonsson B, et al. Annual screening detects celiac disease in children with type 1 diabetes. Pediatr Diabetes 2008;9(Part II):354-9.
  40. 40. ISPAD Clinical Practice Consensus Guidelines 2009 Compendium. Pediatric Diabetes 2009;10(Suppl. 12): 1-2 doi: 10.1111/j.1399-5448.2009.00577.x © 2009 John Wiley & Sons A/S.
  41. 41. Hampson SE, Skinner TC, Hart J, Storey L, Gage H, Foxcroft D, et al. Effects of educational and psychosocial interventions for adolescents with diabetes mellitus: a systematic review. Health Technol Assess 2001;5:1-79.
  42. 42. De Weerdt I, Visser AP, Kok GJ, et al. Randomized controlled multicentre evaluation of an education programme fir insulin-treated diabetic patients: effects on metabolic control, quality of life and costs of therapy. Diabet Med 1991;8:338-45.
  43. 43. Lennon GM, Taylor KG, Debney I, Bailey CJ. Knowledge, attitudes, technical competences, and blood glucose control of Type 1diabetic patients during and after an educational programme. Diabet Med 1990;7:825-32.
  44. 44. Couch R, Jetha M, Dryden DM, Hooton N, Liang Y, Durect T, et al. Diabetes Education for Children with Type 1 Diabetes Mellitus and Their Families. Evidence Report/Technology Assessment No.166.(Prepared by the University of Alberta/Capital Health Evidence-based Practice Center under Contract No.290-02-0023) AHRQ Publication No.08-E011. Rockville,MD:Agency for Healthcare Research and Quality 2008.
  45. 45. Zhang X, Norris SL, Chowdhury FM, et al. The Effects of Interventions on Health-Related Quality of Life Among Persons With Diabetes A Systematic Review. Med Care 2007;45: 820-34.
  46. 46. Murphy HR, Wadham C, Rayman G, Skinner TC. Approaches to integrating paediatric diabetes care and structured education: experiences from the Families, Adolescents, and Children’s Teamwork Study (FACTS). Diabet Med 2007;24:1261-8.
  47. 47. Hermanns N, Kulzer B, Kubiak T, Krichbaum M, Haak T. The effect of an education programme (HyPOS) to treat hypoglycaemia problems in patients with type 1 diabetes. Diabetes Metab Res Rev 2007;23:528-38.
  48. 48. Training in flexible, intensive insulin management to enable dietary freedom in people with type 1 diabetes: dose adjustment for normal eating (DAFNE) randomised controlled trial. BMJ 2002 Oct 5;325(7367):746-51.
  49. 49. Swift PGF. ISPAD Clinical Practice Consensus Guidelines 2006-2007. Diabetes Educ 2007;8:103-9.
  50. 50. Court JM, Cameron FJ, Berg-Kelly K, Swift PGF. ISPAD Clinical Practice Consensus Guidelines 2006-2007.Diabetes in adolescence. Pediatr Diabetes 2008;9(PartI):255-62.
  51. 51. American Diabetes Association (ADA). Standards of Medical Care in Diabetes. Diabetes Care 2008;31(S1).
  52. 52. Funell MM, Brown TL, Childs BP, Hass LB, Hosey GM, Jensen B, et al. National Standards for Diabetes Self-Management Education. Diabetes Care 2008;31(Sup 1).
  53. 53. Checklist for therapeutic patient education. DESG Teaching Letter Number 11 2009.
  54. 54. Patient Education. DESG Teaching Letter Number 7 2009.
  55. 55. Bailey BJ, Kahn A. Apportioning illness management authority: how diabetic individuals evaluate The DAWN (Diabetes Attitudes, Wishes and Needs) Study. Pract Diab Int 2002;19:22a-4a.
  56. 56. Hanson CL, Henggeler SW, Burghen GA. Social competence and parental support as mediators of the link between stress and metabolic control in adolescents with insulin-dependent diabetes mellitus. J Consulting Clin Psychol 1987;55:529-33.
  57. 57. Schafer LC, McCaul KD, Glasgow RE. Supportive and nonsupportive family behaviours: relationships to adherence and metabolic control in persons with type I diabetes. Diabetes Care 1986;9:179-85.
  58. 58. Norris SL, Nichols PJ, Caspersen CJ, et al. The Task Force on Community Preventive Services. Am J Prev Med 2002;22(4S):39.
  59. 59. Karaguzel G, Bircan I, Erisir S, Bundak R. Metabolic control and educational status in children with type 1 diabetes: effects of a summer camp and intensive insulin treatment. Acta Diabetologica 2005 Dec;42(4):156-61.
  60. 60. Gunasekera H, Ambler G. Safety and efficacy of blood glucose management practices at a diabetes camp. Journal of Paediatrics & Child Health 42(10):643-8, 2006 Oct.
  61. 61. Garcia-Perez L, Perestelo-Perez L, Serrano-Aguilar P, Del MT-M. Effectiveness of a psychoeducative intervention in a summer camp for children with type 1 diabetes mellitus. Diabetes Educator 2010 Mar;36(2):310-7.
  62. 62. Wang YC, Stewart S, Tuli E, White P. Improved glycemic control in adolescents with type 1 diabetes mellitus who attend diabetes camp. Pediatric Diabetes 2008 Feb;9(1):29-34.
  63. 63. Santiprabhob J, Likitmaskul S, Kiattisakthavee P, Weerakulwattana P, Chaichanwattanakul K, Nakavachara P, et al. Glycemic control and the psychosocial benefits gained by patients with type 1 diabetes mellitus attending the diabetes camp. Patient Education & Counseling 2008 Oct;73(1):60-6.
  64. 64. Franz MJ, Powers MA, Leontos C, Holzmeister LA, Kulkarni K, Monk A, et al. The evidence for medical nutrition therapy for type 1 and type 2 diabetes in adults. J Am Diet Assoc 2010 Dec;110(12):1852-89.
  65. 65. Boden G, Sargrad K, Homko C, Mozzoli M, Stein TP. Effect of a low-carbohydrate diet on appetite, blood glucose levels, and insulin resistance in obese patients with type 2 diabetes. Ann Intern Med 2005 Mar 15;142(6):403-11.
  66. 66. Nielsen JV, Jonsson E, Ivarsson A. A low carbohydrate diet in type 1 diabetes: clinical experience— a brief report. Ups J Med Sci 2005;110(3):267-73.
  67. 67. Wolever TM, Hamad S, Chiasson JL, Josse RG, Leiter LA, Rodger NW, et al. Day-to-day consistency in amount and source of carbohydrate intake associated with improved blood glucose control in type 1 diabetes. J Am Coll Nutr 1999 Jun;18(3):242-7.
  68. 68. DCCT. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. New England Journal of Medicine 1993 Sep 30;329(14):977-86.
  69. 69. Lowe J, Linjawi S, Mensch M, James K, Attia J. Flexible eating and flexible insulin dosing in patients with diabetes: Results of an intensive self-management course. Diabetes Res Clin Pract 2008 Jun;80(3):439-43.
  70. 70. Garg A, Bantle JP, Henry RR, Coulston AM, Griver KA, Raatz SK, et al. Effects of varying carbohydrate content of diet in patients with non-insulin-dependent diabetes mellitus. JAMA 1994 May 11;271(18):1421-8.
  71. 71. Gerhard GT, Ahmann A, Meeuws K, McMurry MP, Duell PB, Connor WE. Effects of a low-fat diet compared with those of a high-monounsaturated fat diet on body weight, plasma lipids and lipoproteins, and glycemic control in type 2 diabetes. Am J Clin Nutr 2004 Sep;80(3):668-73.
  72. 72. Komiyama N, Kaneko T, Sato A, Sato W, Asami K, Onaya T, et al. The effect of high carbohydrate diet on glucose tolerance in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 2002 Sep;57(3):163-70.
  73. 73. Xu J, Eilat-Adar S, Loria CM, Howard BV, Fabsitz RR, Begum M, et al. Macronutrient intake and glycemic control in a population-based sample of American Indians with diabetes: the Strong Heart Study. Am J Clin Nutr 2007 Aug;86(2):480-7.
  74. 74. Delahanty LM, Nathan DM, Lachin JM, Hu FB, Cleary PA, Ziegler GK, et al. Association of diet with glycated haemoglobin during intensive treatment of type 1 diabetes in the Diabetes Control and Complications Trial. Am J Clin Nutr 2009 Feb;89(2):518-24.
  75. 75. Chantelau EA, Gosseringer G, Sonnenberg GE, Berger M. Moderate intake of sucrose does not impair metabolic control in pump-treated diabetic out-patients. Diabetologia 1985 Apr;28(4):204-7.
  76. 76. Peterson DB, Lambert J, Gerring S, Darling P, Carter RD, Jelfs R, et al. Sucrose in the diet of diabetic patients—just another carbohydrate? Diabetologia 1986 Apr;29(4):216-20.
  77. 77. Bantle JP, Laine DC, Thomas JW. Metabolic effects of dietary fructose and sucrose in types I and II diabetic subjects. JAMA 1986 Dec 19;256(23):3241-6.
  78. 78. Buysschaert M, Sory R, Mpoy M, Lambert AE. Effect of the addition of simple sugars to mixed meals on the glycemic control of insulin treated diabetic patients. Diabete Metab 1987 Nov;13(6):625-9.
  79. 79. Cooper PL, Wahlqvist ML, Simpson RW. Sucrose versus saccharin as an added sweetener in non-insulin-dependent diabetes: short- and medium-term metabolic effects. Diabet Med 1988 Oct;5(7):676-80.
  80. 80. Santacroce G, Forlani G, Giangiulio S, Galuppi V, Pagani M, Vannini P. Long-term effects of eating sucrose on metabolic control of type 1 (insulin-dependent) diabetic outpatients. Acta Diabetol Lat 1990 Oct;27(4):365-70.
  81. 81. Loghmani E, Rickard K, Washburne L, Vandagriff J, Fineberg N, Golden M. Glycemic response to sucrose-containing mixed meals in diets of children of with insulin-dependent diabetes mellitus. J Pediatr 1991 Oct;119(4):531-7.
  82. 82. Bantle JP, Swanson JE, Thomas W, Laine DC. Metabolic effects of dietary sucrose in type II diabetic subjects. Diabetes Care 1993 Sep;16(9):1301-5.
  83. 83. Schwingshandl J, Rippel S, Unterluggauer M, Borkenstein M. Effect of the introduction of dietary sucrose on metabolic control in children and adolescents with type I diabetes. Acta Diabetol 1994 Dec;31(4):205-9.
  84. 84. Malerbi DA, Paiva ES, Duarte AL, Wajchenberg BL. Metabolic effects of dietary sucrose and fructose in type II diabetic subjects. Diabetes Care 1996 Nov;19(11):1249-56.
  85. 85. Nadeau J, Koski KG, Strychar I, Yale JF. Teaching subjects with type 2 diabetes how to incorporate sugar choices into their daily meal plan promotes dietary compliance and does not deteriorate metabolic profile. Diabetes Care 2001 Feb;24(2):222-7.
  86. 86. Coulston AM, Hollenbeck CB, Donner CC, Williams R, Chiou YA, Reaven GM. Metabolic effects of added dietary sucrose in individuals with noninsulin-dependent diabetes mellitus (NIDDM). Metabolism 1985 Oct;34(10):962-6.
  87. 87. Maran A, Crazzolara D, Nicoletti M, Costa S, Dal Pos M, Tiengo A, et al. A randomized crossover study to compare continuous subcutaneous insulin infusion (CSII) with multiple daily injection (MDI) in type 1 diabetic patients previously treated with CSII. Diabetologia 2005;48:A328.
  88. 88. Mezitis NH, Maggio CA, Koch P, Quddoos A, Allison DB, Pi-Sunyer FX. Glycemic effect of a single high oral dose of the novel sweetener sucralose in patients with diabetes. Diabetes Care 1996 Sep;19(9):1004-5.
  89. 89. Grotz VL, Henry RR, McGill JB, Prince MJ, Shamoon H, Trout JR, et al. Lack of effect of sucralose on glucose homeostasis in subjects with type 2 diabetes. J Am Diet Assoc 2003 Dec;103(12):1607-12.
  90. 90. Reyna NY, Cano C, Bermudez VJ, Medina MT, Souki AJ, Ambard M, et al. Sweeteners and beta-glucans improve metabolic and anthropometrics variables in well controlled type 2 diabetic patients. Am J Ther 2003 Nov;10(6):438-43.
  91. 91. Mackenzie T, Brooks B, O’Connor G. Beverage intake, diabetes, and glucose control of adults in America. Ann Epidemiol 2006 Sep;16(9):688-91.
  92. 92. Barriocanal LA, Palacios M, Benitez G, Benitez S, Jimenez JT, Jimenez N, et al. Apparent lack of pharmacological effect of steviol glycosides used as sweeteners in humans. A pilot study of repeated exposures in some normotensive and hypotensive individuals and in Type 1 and Type 2 diabetics. Regul Toxicol Pharmacol 2008 Jun;51(1):37-41.
  93. 93. Maki KC, Curry LL, Reeves MS, Toth PD, McKenney JM, Farmer MV, et al. Chronic consumption of rebaudioside A, a steviol glycoside, in men and women with type 2 diabetes mellitus. Food Chem Toxicol 2008 Jul;46 Suppl 7:S47-S53.
  94. 94. Murillo S. CIBER de Diabetes y Enfermedades Metabólicas Asociadas. Hospital Clinic de Barcelona 2008.
  95. 95. Bantle JP. Dietary fructose and metabolic syndrome and diabetes. J Nutr 2009 Jun;139(6):1263S- 8S.
  96. 96. Hallfrisch J, Reiser S, Prather ES. Blood lipid distribution of hyperinsulinemic men consuming three levels of fructose. Am J Clin Nutr 1983 May;37(5):740-8.
  97. 97. Reiser S, Powell AS, Scholfield DJ, Panda P, Ellwood KC, Canary JJ. Blood lipids, lipoproteins, apoproteins, and uric acid in men fed diets containing fructose or high-amylose cornstarch. Am J Clin Nutr 1989 May;49(5):832-9.
  98. 98. Wolever TM, Jenkins DJ, Jenkins AL, Josse RG. The glycemic index: methodology and clinical implications. Am J Clin Nutr 1991 Nov;54(5):846-54.
  99. 99. Fontvieille AM, Rizkalla SW, Penfornis A, Acosta M, Bornet FR, Slama G. The use of low glycaemic index foods improves metabolic control of diabetic patients over five weeks. Diabet Med 1992 Jun;9(5):444-50.
  100. 100. Wolever TM, Nguyen PM, Chiasson JL, Hunt JA, Josse RG, Palmason C, et al. Determinants of diet glycemic index calculated retrospectively from diet records of 342 individuals with non-insulin-dependent diabetes mellitus. Am J Clin Nutr 1994 Jun;59(6):1265-9.
  101. 101. Gilbertson HR, Brand-Miller JC, Thorburn AW, Evans S, Chondros P, Werther GA. The effect of flexible low glycemic index dietary advice versus measured carbohydrate exchange diets on glycemic control in children with type 1 diabetes. Diabetes Care 2001 Jul;24(7):1137-43.
  102. 102. Gilbertson HR, Thorburn AW, Brand-Miller JC, Chondros P, Werther GA. Effect of lowglycemic- index dietary advice on dietary quality and food choice in children with type 1 diabetes. Am J Clin Nutr 2003 Jan;77(1):83-90.
  103. 103. Buyken AE, Toeller M, Heitkamp G, Karamanos B, Rottiers R, Muggeo M, et al. Glycemic index in the diet of European outpatients with type 1 diabetes: relations to glycated hemoglobin and serum lipids. Am J Clin Nutr 2001 Mar;73(3):574-81.
  104. 104. Brand-Miller J, Hayne S, Petocz P, Colagiuri S. Low-glycemic index diets in the management of diabetes: a meta-analysis of randomized controlled trials. Diabetes Care 2003 Aug;26(8):2261-7.
  105. 105. Burani J, Longo PJ. Low-glycemic index carbohydrates: an effective behavioral change for glycemic control and weight management in patients with type 1 and 2 diabetes. Diabetes Educ 2006 Jan;32(1):78-88.
  106. 106. Thomas D, Elliott EJ. Low glycaemic index, or low glycaemic load, diets for diabetes mellitus. Cochrane Database Syst Rev 2009;(1):CD006296.
  107. 107. Nansel TR, Gellar L, McGill A. Effect of varying glycemic index meals on blood glucose control assessed with continuous glucose monitoring in youth with type 1 diabetes on basalbolus insulin regimens. Diabetes Care 2008 Apr;31(4):695-7.
  108. 108. Rovner AJ, Nansel TR, Gellar L. The effect of a low-glycemic diet vs a standard diet on blood glucose levels and macronutrient intake in children with type 1 diabetes. J Am Diet Assoc 2009 Feb;109(2):303-7.
  109. 109. Chandalia M, Garg A, Lutjohann D, von BK, Grundy SM, Brinkley LJ. Beneficial effects of high dietary fiber intake in patients with type 2 diabetes mellitus. N Engl J Med 2000 May 11;342(19):1392-8.
  110. 110. Hagander B, Asp NG, Efendic S, Nilsson-Ehle P, Schersten B. Dietary fiber decreases fasting blood glucose levels and plasma LDL concentration in noninsulin-dependent diabetes mellitus patients. Am J Clin Nutr 1988 May;47(5):852-8.
  111. 111. Giacco R, Parillo M, Rivellese AA, Lasorella G, Giacco A, D’Episcopo L, et al. Long-term dietary treatment with increased amounts of fiber-rich low-glycemic index natural foods improves blood glucose control and reduces the number of hypoglycemic events in type 1 diabetic patients. Diabetes Care 2000 Oct;23(10):1461-6.
  112. 112. Kinmonth AL, Angus RM, Jenkins PA, Smith MA, Baum JD. Whole foods and increased dietary fibre improve blood glucose control in diabetic children. Arch Dis Child 1982 Mar;57(3):187-94.
  113. 113. Del TE, Lintas C, Clementi A, Marcelli M. Soluble and insoluble dietary fibre in diabetic diets. Eur J Clin Nutr 1988 Apr;42(4):313-9.
  114. 114. Riccardi G, Rivellese A, Pacioni D, Genovese S, Mastranzo P, Mancini M. Separate influence of dietary carbohydrate and fibre on the metabolic control in diabetes. Diabetologia 1984 Feb;26(2):116-21.
  115. 115. Story L, Anderson JW, Chen WJ, Karounos D, Jefferson B. Adherence to high-carbohydrate, high-fiber diets: long-term studies of non-obese diabetic men. J Am Diet Assoc 1985 Sep;85(9):1105-10.
  116. 116. Lindsay AN, Hardy S, Jarrett L, Rallison ML. High-carbohydrate, high-fiber diet in children with type I diabetes mellitus. Diabetes Care 1984 Jan;7(1):63-7.
  117. 117. McCulloch DK, Mitchell RD, Ambler J, Tattersall RB. A prospective comparison of ‘conventional’ and high carbohydrate/high fibre/low fat diets in adults with established type 1 (insulindependent) diabetes. Diabetologia 1985 Apr;28(4):208-12.
  118. 118. Buyken AE, Toeller M, Heitkamp G, Vitelli F, Stehle P, Scherbaum WA, et al. Relation of fibre intake to HbA1c and the prevalence of severe ketoacidosis and severe hypoglycaemia. EURODIAB IDDM Complications Study Group. Diabetologia 1998 Aug;41(8):882-90.
  119. 119. Shimakawa T, Warram JH, Herrera-Acena MG, Krolewski AS. Usual dietary intake and hemoglobin A1 level in patients with insulin-dependent diabetes. J Am Diet Assoc 1993 Dec;93(12):1409-12, 1415.
  120. 120. Van HL, McCoin M, Kris-Etherton PM, Burke F, Carson JA, Champagne CM, et al. The evidence for dietary prevention and treatment of cardiovascular disease. J Am Diet Assoc 2008 Feb;108(2):287-331.
  121. 121. Nordt TK, Besenthal I, Eggstein M, Jakober B. Influence of breakfasts with different nutrient contents on glucose, C peptide, insulin, glucagon, triglycerides, and GIP in non-insulin-dependent diabetics. Am J Clin Nutr 1991 Jan;53(1):155-60.
  122. 122. Gannon MC, Nuttall JA, Damberg G, Gupta V, Nuttall FQ. Effect of protein ingestion on the glucose appearance rate in people with type 2 diabetes. J Clin Endocrinol Metab 2001 Mar;86(3):1040-7.
  123. 123. Parker B, Noakes M, Luscombe N, Clifton P. Effect of a high-protein, high-monounsaturated fat weight loss diet on glycemic control and lipid levels in type 2 diabetes. Diabetes Care 2002 Mar;25(3):425-30.
  124. 124. Luscombe ND, Clifton PM, Noakes M, Parker B, Wittert G. Effects of energy-restricted diets containing increased protein on weight loss, resting energy expenditure, and the thermic effect of feeding in type 2 diabetes. Diabetes Care 2002 Apr;25(4):652-7.
  125. 125. Nuttall FQ, Gannon MC, Saeed A, Jordan K, Hoover H. The metabolic response of subjects with type 2 diabetes to a high-protein, weight-maintenance diet. J Clin Endocrinol Metab 2003 Aug;88(8):3577-83.
  126. 126. Gannon MC, Nuttall FQ, Saeed A, Jordan K, Hoover H. An increase in dietary protein improves the blood glucose response in persons with type 2 diabetes. Am J Clin Nutr 2003 Oct;78(4):734-41.
  127. 127. Brinkworth GD, Noakes M, Parker B, Foster P, Clifton PM. Long-term effects of advice to consume a high-protein, low-fat diet, rather than a conventional weight-loss diet, in obese adults with type 2 diabetes: one-year follow-up of a randomised trial. Diabetologia 2004 Oct;47(10):1677-86.
  128. 128. Robertson L, Waugh N, Robertson A. Protein restriction for diabetic renal disease. Cochrane Database Syst Rev 2007;(4):CD002181.
  129. 129. Pan Y, Guo LL, Jin HM. Low-protein diet for diabetic nephropathy: a meta-analysis of randomized controlled trials. Am J Clin Nutr 2008 Sep;88(3):660-6.
  130. 130. Raal FJ, Kalk WJ, Lawson M, Esser JD, Buys R, Fourie L, et al. Effect of moderate dietary protein restriction on the progression of overt diabetic nephropathy: a 6-mo prospective study. Am J Clin Nutr 1994 Oct;60(4):579-85.
  131. 131. Hansen HP, Christensen PK, Tauber-Lassen E, Klausen A, Jensen BR, Parving HH. Lowprotein diet and kidney function in insulin-dependent diabetic patients with diabetic nephropathy. Kidney Int 1999 Feb;55(2):621-8.
  132. 132. Dussol B, Iovanna C, Raccah D, Darmon P, Morange S, Vague P, et al. A randomized trial of low-protein diet in type 1 and in type 2 diabetes mellitus patients with incipient and overt nephropathy. J Ren Nutr 2005 Oct;15(4):398-406.
  133. 133. Meloni C, Morosetti M, Suraci C, Pennafina MG, Tozzo C, Taccone-Gallucci M, et al. Severe dietary protein restriction in overt diabetic nephropathy: benefits or risks? J Ren Nutr 2002 Apr;12(2):96-101.
  134. 134. Hansen HP, Tauber-Lassen E, Jensen BR, Parving HH. Effect of dietary protein restriction on prognosis in patients with diabetic nephropathy. Kidney Int 2002 Jul;62(1):220-8.
  135. 135. Azadbakht L, Shakerhosseini R, Atabak S, Jamshidian M, Mehrabi Y, Esmaill-Zadeh A. Beneficiary effect of dietary soy protein on lowering plasma levels of lipid and improving kidney function in type II diabetes with nephropathy. Eur J Clin Nutr 2003 Oct;57(10):1292-4.
  136. 136. Meloni C, Tatangelo P, Cipriani S, Rossi V, Suraci C, Tozzo C, et al. Adequate protein dietary restriction in diabetic and nondiabetic patients with chronic renal failure. J Ren Nutr 2004 Oct;14(4):208-13.
  137. 137. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005 Dec 22;353(25):2643-53.
  138. 138. Mayer-Davis EJ, Levin S, Marshall JA. Heterogeneity in associations between macronutrient intake and lipoprotein profile in individuals with type 2 diabetes. Diabetes Care 1999 Oct;22(10):1632-9.
  139. 139. Orchard TJ, Forrest KY, Kuller LH, Becker DJ. Lipid and blood pressure treatment goals for type 1 diabetes: 10-year incidence data from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care 2001 Jun;24(6):1053-9.
  140. 140. Mukamal KJ, Nesto RW, Cohen MC, Muller JE, Maclure M, Sherwood JB, et al. Impact of diabetes on long-term survival after acute myocardial infarction: comparability of risk with prior myocardial infarction. Diabetes Care 2001 Aug;24(8):1422-7.
  141. 141. Faulkner MS, Chao WH, Kamath SK, Quinn L, Fritschi C, Maggiore JA, et al. Total homocysteine, diet, and lipid profiles in type 1 and type 2 diabetic and nondiabetic adolescents. J Cardiovasc Nurs 2006 Jan;21(1):47-55.
  142. 142. Buccino J, Murray K, Farmer S, Assor E, Daneman D. Systematic review of the dietary management of children with type 1 diabetes. Canadian Journal of Diabetes 2004;28:219-25.
  143. 143. Goksen D, Darcan S, Buyukinan M, Kose T, Erermis S, Coker M. The effect of insulin glargine and nutritional model on metabolic control, quality of life and behavior in children and adolescents with type 1 diabetes mellitus. Acta Diabetol 2008 Mar;45(1):47-52.
  144. 144. Kalergis M, Pacaud D, Strychar I, Meltzer S, Jones PJ, Yale JF. Optimizing insulin delivery: assessment of three strategies in intensive diabetes management. Diabetes Obes Metab 2000 Oct;2(5):299-305.
  145. 145. Campaigne BN, Gilliam TB, Spencer ML, Lampman RM, Schork MA. Effects of a physical activity program on metabolic control and cardiovascular fitness in children with insulin-dependent diabetes mellitus. Diabetes Care 1984 Jan;7(1):57-62.
  146. 146. Huttunen NP, Lankela SL, Knip M, Lautala P, Kaar ML, Laasonen K, et al. Effect of once-aweek training program on physical fitness and metabolic control in children with IDDM. Diabetes Care 1989 Nov;12(10):737-40.
  147. 147. Ruzic L, Sporis G, Matkovic BR. High volume-low intensity exercise camp and glycemic control in diabetic children. J Paediatr Child Health 2008 Mar;44(3):122-8.
  148. 148. Herbst A, Bachran R, Kapellen T, Holl RW. Effects of regular physical activity on control of glycemia in pediatric patients with type 1 diabetes mellitus. Arch Pediatr Adolesc Med 2006 Jun;160(6):573-7.
  149. 149. Laaksonen DE, Atalay M, Niskanen LK, Mustonen J, Sen CK, Lakka TA, et al. Aerobic exercise and the lipid profile in type 1 diabetic men: a randomized controlled trial. Med Sci Sports Exerc 2000 Sep;32(9):1541-8.
  150. 150. Lehmann R, Kaplan V, Bingisser R, Bloch KE, Spinas GA. Impact of physical activity on cardiovascular risk factors in IDDM. Diabetes Care 1997 Oct;20(10):1603-11.
  151. 151. Schneider SH, Khachadurian AK, Amorosa LF, Clemow L, Ruderman NB. Ten-year experience with an exercise-based outpatient life-style modification program in the treatment of diabetes mellitus. Diabetes Care 1992 Nov;15(11):1800-10.
  152. 152. Ligtenberg PC, Blans M, Hoekstra JB, van dT, I, Erkelens DW. No effect of long-term physical activity on the glycemic control in type 1 diabetes patients: a cross-sectional study. Neth J Med 1999 Aug;55(2):59-63.
  153. 153. Conn VS, Hafdahl AR, Lemaster JW, Ruppar TM, Cochran JE, Nielsen PJ. Meta-analysis of health behavior change interventions in type 1 diabetes. Am J Health Behav 2008 May;32(3):315-29.
  154. 154. Pedersen BK, Saltin B. Evidence for prescribing exercise as therapy in chronic disease. Scand J Med Sci Sports 2006 Feb;16 Suppl 1:3-63.
  155. 155. Wasserman DH, Zinman B. Exercise in individuals with IDDM. Diabetes Care 1994 Aug;17(8):924-37.
  156. 156. Veves A, Saouaf R, Donaghue VM, Mullooly CA, Kistler JA, Giurini JM, et al. Aerobic exercise capacity remains normal despite impaired endothelial function in the micro- and macrocirculation of physically active IDDM patients. Diabetes 1997 Nov;46(11):1846-52.
  157. 157. Wallberg-Henriksson H, Gunnarsson R, Henriksson J, Ostman J, Wahren J. Influence of physical training on formation of muscle capillaries in type I diabetes. Diabetes 1984 Sep;33(9):851-7.
  158. 158. Yki-Jarvinen H, DeFronzo RA, Koivisto VA. Normalization of insulin sensitivity in type I diabetic subjects by physical training during insulin pump therapy. Diabetes Care 1984 Nov;7(6):520-7.
  159. 159. Wallberg-Henriksson H, Gunnarsson R, Rossner S, Wahren J. Long-term physical training in female type 1 (insulin-dependent) diabetic patients: absence of significant effect on glycaemic control and lipoprotein levels. Diabetologia 1986 Jan;29(1):53-7.
  160. 160. Kavookjian J, Elswick BM, Whetsel T. Interventions for being active among individuals with diabetes: a systematic review of the literature. Diabetes Educ 2007 Nov;33(6):962-88.
  161. 161. Carral F, Gutierrez JV, Ayala C, Garcia C, Silva JJ, Aguilar M. Impacto de la actividad física sobre el control metabólico y el desarrollo de complicaciones crónicas en pacientes con diabetes mellitus tipo 1. Endocrinol Nutr 2010; 57 :268-76 - vol 57 núm 06 2010.
  162. 162. Nielsen PJ, Hafdahl AR, Conn VS, Lemaster JW, Brown SA. Meta-analysis of the effect of exercise interventions on fitness outcomes among adults with type 1 and type 2 diabetes. Diabetes Res Clin Pract 2006 Nov;74(2):111-20.
  163. 163. Marrone S, Plume JW, Kerr P, Pignol A, Vogeltanz-Holm N, Holm J, et al. The role of freeplay physical activity in healthy blood glucose maintenance in children with type 1 diabetes mellitus. Psychol Health Med 2009 Jan;14(1):48-52.
  164. 164. Durak EP, Jovanovic-Peterson L, Peterson CM. Randomized crossover study of effect of resistance training on glycemic control, muscular strength, and cholesterol in type I diabetic men. Diabetes Care 1990 Oct;13(10):1039-43.
  165. 165. Ramalho AC, de Lourdes LM, Nunes F, Cambui Z, Barbosa C, Andrade A, et al. The effect of resistance versus aerobic training on metabolic control in patients with type-1 diabetes mellitus. Diabetes Res Clin Pract 2006 Jun;72(3):271-6.
  166. 166. Delahanty L, Simkins SW, Camelon K. Expanded role of the dietitian in the Diabetes Control and Complications Trial: implications for clinical practice. The DCCT Research Group. J Am Diet Assoc 1993 Jul;93(7):758-64, 767.
  167. 167. EDIC. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group.[Erratum appears in N Engl J Med 2000 May 4;342(18):1376]. New England Journal of Medicine 2000 Feb 10;342(6):381-90.
  168. 168. Stettler C, Allemann S, Juni P, Cull CA, Holman RR, Egger M, et al. Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: Meta-analysis of randomized trials. Am Heart J 2006 Jul;152(1):27-38.
  169. 169. Shankar A, Klein R, Klein BE, Moss SE. Association between glycosylated hemoglobin level and cardiovascular and all-cause mortality in type 1 diabetes. Am J Epidemiol 2007 Aug 15;166(4):393-402.
  170. 170. Saleem T, Mohammad KH, bdel-Fattah MM, Abbasi AH. Association of glycosylated haemoglobin level and diabetes mellitus duration with the severity of coronary artery disease. Diab Vasc Dis Res 2008 Sep;5(3):184-9.
  171. 171. Goberna R, Aguilar Diosdado M, Santos Rey K, Mateo J. Documento de consenso para la armonización de resultados de HbA1c en España. Av Diabetol Publisher ahead of Print Publisher online ahead of print 2009 2009.
  172. 172. American Diabetes Association. Consensus statement on the worldwide standardisation of the HbA1c measurement. European Association for the Study of Diabetes,International Federation of Clinical Chemistry and Laboratory Medicine,and the International Diabetes Federation Consensus Committee American Diabetes Association 2007;Diabetología 2007; DOI 0.1007/s00125-007-0789-7.
  173. 173. Gabriely I, Wozniak R, Mevorach M, Kaplan J, Aharon Y, Shamoon H. Transcutaneous glucose measurement using near-infrared spectroscopy during hypoglycemia. Diabetes Care 1999 Dec;22(12):2026-32.
  174. 174. Muller UA, Mertes B, Fischbacher C, Jageman KU, Danzer K. Non-invasive blood glucose monitoring by means of near infrared spectroscopy: methods for improving the reliability of the calibration models. International Journal of Artificial Organs 1997;(20):285-90.
  175. 175. Uemura T, Nishida K, Sakakida M, Ichinose K, Shimoda S, Shichiri M. Non-invasive blood glucose measurement by Fourier transform infrared spectroscopic analysis through the mucous membrane of the lip: application of a chalcogenide optical fiber system. Frontiers of Medical and Biological Engineering 1999;9:137-53.
  176. 176. Garg S, Zisser H, Schwartz S, Bailey T, Kaplan R, Ellis S, et al. Improvement in glycemic excursions with a transcutaneous, real-time continuous glucose sensor: a randomized controlled trial. Diabetes Care 2006 Jan;29(1):44-50.
  177. 177. Monsod TP, Flanagan DE, Rife F, Saenz R, Caprio S, Sherwin RS, et al. Do sensor glucose levels accurately predict plasma glucose concentrations during hypoglycemia and hyperinsulinemia? Diabetes Care 2002 May;25(5):889-93.
  178. 178. Gross TM, Bode BW, Einhorn D, Kayne DM, Reed JH, White NH, et al. Performance evaluation of the MiniMed continuous glucose monitoring system during patient home use. Diabetes Technology & Therapeutics 2(1):49-56, 2000.
  179. 179. Chetty VT, Almulla A, Odueyungbo A, Thabane L. The effect of continuous subcutaneous glucose monitoring (CGMS) versus intermittent whole blood finger-stick glucose monitoring (SBGM) on hemoglobin A1c (HBA1c) levels in Type I diabetic patients: a systematic review. Diabetes Res Clin Pract 2008 Jul;81(1):79-87.
  180. 180. Golicki DT, Golicka D, Groele L, Pankowska E. Continuous Glucose Monitoring System in children with type 1 diabetes mellitus: a systematic review and meta-analysis. Diabetologia 2008 Feb;51(2):233-40.
  181. 181. Chico A, Vidal-Rios P, Subira M, Novials A. The continuous glucose monitoring system is useful for detecting unrecognized hypoglycemias in patients with type 1 and type 2 diabetes but is not better than frequent capillary glucose measurements for improving metabolic control. Diabetes Care 2003 Apr;26(4):1153-7.
  182. 182. Murphy HR, Rayman G, Lewis K, Kelly S, Johal B, Duffield K, et al. Effectiveness of continuous glucose monitoring in pregnant women with diabetes: randomised clinical trial. BMJ 2008;337:a1680.
  183. 183. Hirsch IB, Abelseth J, Bode BW, Fischer JS, Kaufman FR, Mastrototaro J, et al. Sensoraugmented insulin pump therapy: results of the first randomized treat-to-target study. Diabetes Technol Ther 2008 Oct;10(5):377-83.
  184. 184. Tamborlane WV, Beck RW, Bode BW, Buckingham B, Chase HP, Clemons R, et al. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med 2008 Oct 2;359(14):1464-76.
  185. 185. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. The Effect of Continuous Glucose Monitoring in Well-Controlled Type 1 Diabetes. Diabetes Care 2009 Aug;32 no.8:1378-83.
  186. 186. Clar C, Waugh N, Thomas S. Hospitalización sistemática versus atención ambulatoria o domiciliaria de niños con diagnóstico de diabetes mellitus tipo 1 (Revisión Cochrane traducida). Biblioteca Cochrane Plus 2008;Numero 2.
  187. 187. Chase HP, Crews KR, Garg S, Crews MJ, Cruickshanks KJ, Klingensmith G, et al. Outpatient management vs in-hospital management of children with new-onset diabetes. Clinical Pediatrics 31(8):450-6, 1992 Aug.
  188. 188. Dougherty GE, Soderstrom L, Schiffrin A. An economic evaluation of home care for children with newly diagnosed diabetes: results from a randomized controlled trial. Medical Care 36(4):586-98, 1998 Apr.
  189. 189. Simell T, Putto-Laurila A, Näntö-Salonen K, Salomaa P, Piekkala P, Hakalax J, et al. Randomized prospective trial of ambulatory treatment and one-week hospitalisation of children with newly diagnosed IDDM. Diabetes 1995;Suppl 1:162A.
  190. 190. Srinivasan S, Craig ME, Beeney L, Hayes R, Harkin N, Ambler GR, et al. An ambulatory stabilisation program for children with newly diagnosed type 1 diabetes. Medical Journal of Australia 180(6):277-80, 2004 Mar 15.
  191. 191. Siminerio LM, Charron-Prochownik D, Banion C, Schreiner B. Comparing outpatient and inpatient diabetes education for newly diagnosed pediatric patients. Diabetes Educator 25(6):895-906, 1999 Nov;-Dec.
  192. 192. Galatzer A, Amir S, Gil R, Karp M, Laron Z. Crisis intervention program in newly diagnosed diabetic children. Diabetes Care 5(4):414-9, 1982 Jul;-Aug.
  193. 193. Spaulding RH, Spaulding WB. The diabetic day-care unit. II. Comparison of patients and costs of initiating insulin therapy in the unit and a hospital. Can Med Assoc J 1976 May 8;114(9):780-3.
  194. 194. Anderson JH, Jr., Brunelle RL, Koivisto VA, Pfutzner A, Trautmann ME, Vignati L, et al. Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulinanalog treatment. Multicenter Insulin Lispro Study Group. Diabetes 1997 Feb;46(2):265-70.
  195. 195. Ciofetta M, Lalli C, Del Sindaco P, Torlone E, Pampanelli S, Mauro L, et al. Contribution of postprandial versus interprandial blood glucose to HbA1c in type 1 diabetes on physiologic intensive therapy with lispro insulin at mealtime. Diabetes Care 1999;22:795-800.
  196. 196. Garg SK, Carmain JA, Braddy KC, Anderson JH, Vignati L, Jennings MK, et al. Pre-meal insulin analogue insulin lispro vs Humulin R insulin treatment in young subjects with type 1 diabetes. Diabet Med 1996 Jan;13(1):47-52.
  197. 197. Heller SR, Amiel SA, Mansell P. Effect of the fast-acting insulin analog lispro on the risk of nocturnal hypoglycemia during intensified insulin therapy. U.K. Lispro Study Group. Diabetes Care 1999 Oct;22(10):1607-11.
  198. 198. Janssen MM, Snoek FJ, Masurel N, Hoogma RP, Deville WL, Popp-Snijders C, et al. Optimized basal-bolus therapy using a fixed mixture of 75% lispro and 25% NPL insulin in type 1 diabetes patients: no favorable effects on glycemic control, physiological responses to hypoglycemia, well-being, or treatment satisfaction. Diabetes Care 2000 May;23(5):629-33.
  199. 199. Lalli C, Ciofetta M, Del Sindaco P, Torlone E, Pampanelli S, Compagnucci P. Long-term intensive treatment of type 1 diabetes with the short-acting insulin analog lispro in variable combination with NPH insulin at mealtime. Diabetes Care 1999;22:468-77.
  200. 200. Valle D, Santoro D, Bates P, Scarpa L, Italian Multicentre Lispro Study Group. Italian multicentre study of intensive therapy with insulin lispro in 1184 patients with Type 1 diabetes. Diabetes, Nutrition & Metabolism - Clinical & Experimental 14(3):126-32, 2001 Jun.
  201. 201. Vignati L, Anderson JH, Brunelle RL, Jefferson FL, Richardson M. Improvement of glycemic control with the rapidly absorbed lispro insulin analog in type 1 diabetes. Diabetologia 1994;37(Suppl 1):A78.
  202. 202. Home PD, Lindholm A. Insulin aspart vs. human insulin in the management of long-term blood glucose control in Type 1 diabetes mellitus: a randomized controlled trial. Diabet Med 2000;17:762-70.
  203. 203. Raskin P, Guthrie RA, Leiter L, Riis A, Jovanovic L. Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type diabetes. Diabetes Care 2000;53:583-8.
  204. 204. Tamas G, Marre M, Astorga R, Dedov I, Jacobsen J, Lindholm A, et al. Glycaemic control in type 1 diabetic patients using optimised insulin aspart or human insulin in a randomised multinational study. Diabetes Res Clin Pract 2001;54:105-14.
  205. 205. Annuzzi G, Del Prato S, Arcari R, Bellomo DA, Benzi L, Bruttomesso D, et al. Preprandial combination of lispro and NPH insulin improves overall blood glucose control in type 1 diabetic patients: a multicenter randomized crossover trial. Nutr Metab Cardiovasc Dis 2001;11:168-75.
  206. 206. Caixas A, Perez A, Payes A, Otal C, Carreras G, Ordonez-Llanos J, et al. Effects of a shortacting insulin analog (Insulin Lispro) versus regular insulin on lipid metabolism in insulindependent diabetes mellitus. Metabolism: Clinical and Experimental 1998;47:371-6.
  207. 207. Ferguson SC, Strachan MW, Janes JM, Frier BM. Severe hypoglycaemia in patients with type 1 diabetes and impaired awareness of hypoglycaemia: a comparative study of insulin lispro and regular human insulin. Diabetes Metab Res Rev 2001;17:285-91.
  208. 208. Gale EA. A randomized, controlled trial comparing insulin lispro with human soluble insulin in patients with Type 1 diabetes on intensified insulin therapy.The UK Trial Group. Diabet Med 2000;17:209-14.
  209. 209. Holleman F, Schmitt H, Rottiers R, Rees A, Symanowski S, Anderson JH, et al. Reduced frequency of severe hypoglycemia and coma in well-controlled IDDM patients treated with insulin lispro. Diabetes Care 1997;20:1827-32.
  210. 210. Pfutzner A, Kustner E, Forst T, Schulze-Schleppinghoff B, Trautmann ME, Haslbeck M, et al. Intensive insulin therapy with insulin lispro in patients with type 1 diabetes reduces the frequency of hypoglycemic episodes. Exp Clin Endocrinol Diabetes 1996;104(1):25-30.
  211. 211. Provenzano C, Vero R, Oliva A, Leto G, Puccio L, Vecci E, et al. Lispro insulin in type 1 diabetic patients on a Mediterranean or normal diet: a randomized, cross-over comparative study with regular insulin. Diabetes Nutr Metab 2001;14:133-9.
  212. 212. Vignati L, Anderson JH, Iversen PW. Efficacy of insulin lispro in combination with NPH human insulin twice per day in patients with insulin-dependent or non-insulin-dependent diabetes mellitus. Clin Ther 1997;19:1408-21.
  213. 213. Banerjee S, Tran K, Li H, Cimon K, Daneman D, Simpson S, et al. Short-acting insulin analogues for diabetes mellitus: meta-analysis of clinical outcomes and assesssment of cost effectiveness. Otawa: Canadian Agency for drugs and Technologies in Health 2007.
  214. 214. Siebenhofer A, Plank J, Berghold A, Narath M, Gfrerer R, Pieber TR. Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus. Cochrane Database Syst Rev 2006;(4):CD003287.
  215. 215. Siebenhofer A, Plank J, Berghold A, Horvath K, Sawicki PT, Beck P, et al. Meta-analysis of short acting insulin analogues in adult patients with type 1 diabetes: continuous subcutaneous insulin infusion versus injection theraphy38. Diabetologia 2004;47(11):1895-905.
  216. 216. Plank J, Siebenhofer A, Berghold A, Jeitler K, Horvath K, Mrak P, et al. Systematic review and metaanalysis of short-acting insulin analogues in patients with diabetes mellitus. Arch Intern Med 2005;165(12):1337-44.
  217. 217. Colquitt J, Royle P, Waug N. Are analogue insulins better than soluble in continuous subcutaneous insulina infusion? Results of a meta-analysis. Diabet Med 2003;20(10):863-6.
  218. 218. Brunelle BL, Llewelyn J, Anderson JH, Gale EA, Koivisto VA. Meta-analysis of the effect of insulin lispro on severe hypoglycemia in patients with type 1 diabetes. Diabetes Care 1998;21(10):1726-31.
  219. 219. Jacobsen IB, Henriksen JE, Hother-Nielsen O, Vach W, Beck-Nielsen H. Evidence-based insulin treatment in type 1 diabetes mellitus. Diabetes Res Clin Pract 2009 Oct;86(1):1-10.
  220. 220. Chen JW, Lauritzen T, Bojesen A, Christiansen JS. Multiple mealtime administration of biphasic insulin aspart 30 versus traditional basal-bolus human insulin treatment in patients with type 1 diabetes. Diabetes Obes Metab 2006;8(6):682-9.
  221. 221. Singh SR, Ahmad F, Lal A, Yu C, Bai Z, Bennett H. Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis. CMAJ 2009 Feb 17;180(4):385-97.
  222. 222. Anderson JH, Jr., Brunelle RL, Koivisto VA, Trautmann ME, Vignati L, DiMarchi R. Improved mealtime treatment of diabetes mellitus using an insulin analogue. Multicenter Insulin Lispro Study Group. Clin Ther 1997 Jan;19(1):62-72.
  223. 223. Bode B, Weinstein R, Bell D, McGill J, Nadeau D, Raskin P, et al. Comparison of insulin aspart with buffered regular insulin and insulin lispro in continuous subcutaneous insulin infusion: a randomized study in type 1 diabetes. Diabetes Care 2002 Mar;25(3):439-44.
  224. 224. Del SP, Ciofetta M, Lalli C, Perriello G, Pampanelli S, Torlone E, et al. Use of the shortacting insulin analogue lispro in intensive treatment of type 1 diabetes mellitus: importance of appropriate replacement of basal insulin and time-interval injection-meal. Diabet Med 1998 Jul;15(7):592-600.
  225. 225. Garg SK, Rosenstock J, Ways K. Optimized Basal-bolus insulin regimens in type 1 diabetes: insulin glulisine versus regular human insulin in combination with Basal insulin glargine. Endocr Pract 2005 Jan;11(1):11-7.
  226. 226. Renner R, Pfutzner A, Trautmann M, Harzer O, Sauter K, Landgraf R. Use of insulin lispro in continuous subcutaneous insulin infusion treatment. Results of a multicenter trial. German Humalog-CSII Study Group. Diabetes Care 1999 May;22(5):784-8.
  227. 227. Schmauss S, Konig A, Landgraf R. Human insulin analogue [LYS(B28), PRO(B29)]: the ideal pump insulin? Diabet Med 1998 Mar;15(3):247-9.
  228. 228. Bradley C, Lewis KS. Measures of psychological well-being and treatment satisfaction developed from the responses of people with tablet-treated diabetes. Diabet Med 1990 Jun;7(5):445-51.
  229. 229. Bradley C. A guide to psychological measurement in diabetes research and practice. Handbook of Psychology and Diabetes Routledge 1994.
  230. 230. Cox DJ, Irvine A, Gonder-Frederick L, Nowacek G, Butterfield J. Fear of hypoglycemia: quantification, validation, and utilization. Diabetes Care 1987 Sep;10(5):617-21.
  231. 231. Bott U, Muhlhauser I, Overmann H, Berger M. Validation of a diabetes-specific quality-of-life scale for patients with type 1 diabetes. Diabetes Care 1998 May;21(5):757-69.
  232. 232. Reliability and validity of a diabetes quality-of-life measure for the diabetes control and complications trial (DCCT). The DCCT Research Group. Diabetes Care 1988 Oct;11(9):725-32.
  233. 233. Tubiana-Rufi N, Coutant R, Bloch J, Munz-Licha G, Delcroix C, Montaud-ragideau N, et al. Special management of insulin lispro in continuous subcutaneous insulin infusion in young diabetic children: a randomized cross-over study. Horm Res 2004;62:265-71.
  234. 234. Johansson UB, Adamson UCK, Lins PES, Wredling RAM. Improved blood glucose variability, HBA1C Insuman Infusat and less insulin requirement in IDDM patients using insulin lispro in CSII. The Swedish multicenter lispro insulin study Diabetes Metabolism 2000;26(3):192-6.
  235. 235. Jeitler K, Horvath K, Berghold A, Gratzer TW, Neeser K, Pieber TR, et al. Continuous subcutaneous insulin infusion versus multiple daily insulin injections in patients with diabetes mellitus: systematic review and meta-analysis. Diabetologia 2008;51(6):941-51.
  236. 236. Deeb LC, Holcombe JH, Brunelle R, Zalani S, Brink S, Jenner M, et al. Insulin lispro lowers postprandial glucose in prepubertal children with diabetes. Pediatrics 2001;108:1175-9.
  237. 237. Ford-Adams ME, Murphy NP, Moore EJ, Edge JA, Ong KL, Watts AP, et al. Insulin lispro: a potential role in preventing nocturnal hypoglycaemia in young children with diabetes mellitus. Diabet Med 2003;20:656-60.
  238. 238. Tupola S, Komulainen J, Jääskeläinen J, Sipilä I. Post-prandial insulina lispro vs. human regular insulin in prepubertal children with Type diabetes mellitus. Diabet Med 2001;18:654-8.
  239. 239. Danne T, Rastam J, Odendahl R, Näke A, Schimmel U, Szczepanski R, et al. Parental preference of prandial insulin aspart compared with prepandial human insulin in a basal-bolus scheme with NPH insulin in a 12-wk crossover study of preschool children with type 1 diabetes. Pediatr Diabetes 2007;8(5):278-85.
  240. 240. Holcombe JH, Zalani S, Arora VK, Mast CJ. Comparison of insulin lispro with regular human insulin for the treatment of type 1 diabetes in adolescents. Clin Ther 2002;24(4):626-38.
  241. 241. Mortensen H, Kocova M, Teng LY, Keiding J, Bruckner I, Philotheou A. Biphasic insulin aspart vs. human insulin in adolescents with type diabetes on multiple daily insulin injections. Pediatr Diabetes 2006;7(1):4-10.
  242. 242. Persson B, Swahn ML, Hjertberg R, Hanson U, Nord E, Nordlander E, et al. Insulin lispro theraphy in pregnancies complicated by type diabetes mellitus. Diabetes Res Clin Pract 2002;58:115-21.
  243. 243. Mathiesen ER, Kinsley B, Amiel SA, Heller S, McCance D, Duran S, et al. Insulin Apart Pregnancy Study Group. Maternal Glycemic control and hypoglycemia in type 1 diabetic pregnancy: a randomized trial of insulin aspart versus human insulin in 322 pregnant women. Diabetes Care 2007;30(4):771-6.
  244. 244. Lapolla A, Dalfra MG, Fedele D. Insulin therapy in pregnancy complicated by diabetes: are insulin analogs a new tool? Diabetes Metab Res Rev 2005 May;21(3):241-52.
  245. 245. Hod M, Damm P, Kaaja R, Visser GH, Dunne F, Demidova I, et al. Fetal and perinatal outcomes in type 1 diabetes pregnancy: a randomized study comparing insulin aspart with human insulin in 322 subjects. Am J Obstet Gynecol 2008 Feb;198(2):186-7.
  246. 246. Torlone E, Di CG, Mannino D, Lapolla A. Insulin analogs and pregnancy: an update. Acta Diabetol 2009 Sep;46(3):163-72.
  247. 247. Tran K, Banerjee S, Li H, Cimon K, Daneman D, simpson SH, et al. Long-acting insulin analogues for diabetes mellitus: meta-analysis of clinical outcomes and assessment of cost effectiveness. Otawa: Canadian Agency for drugs and Technologies in Health 2007.
  248. 248. Vardi M, Jacobson E, Nini A, Bitterman H. Insulina de acción intermedia versus insulina de acción prolongada para la diabetes mellitus tipo 1 (Revisión Cochrane traducida). (Traducida de The Cochrane Library, 2008 Issue 3 Chichester, UK: John Wiley & Sons, Ltd ) 2008.
  249. 249. Monami M, Marchionni N, Mannucci E. Long-acting insulin analogues vs. NPH human insulin in type 1 diabetes. A meta-analysis. Diabetes Obes Metab 2009 Apr;11(4):372-8.
  250. 250. Kudva YC, Basu A, Jenkins GD, Pons GM, Quandt LL, Gebel JA, et al. Randomized controlled clinical trial of glargine versus ultralente insulin in the treatment of type 1 diabetes. Diabetes Care 2005;28(1):10-4.
  251. 251. Witthaus E, Stewart J, Bradley C. Treatment satisfaction and psychological well-being with insulina glargine compared with NPH in patients with type 1 diabetes. Diabet Med 2001;18(8):619-25.
  252. 252. Colhoun HM, SDRN Epidemiology Group. Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemilogy Group. Diabetologia 2009;52:1755-65.
  253. 253. Jonasson JM, Ljung R, Talbäck M, Haglund B, Gudbjörnsdóttir S, Steineck G. Insulin glargine use and short-term incidence of malignancies a population-based follow-up study in Sweden. Diabetologia 2009;52:1732-44.
  254. 254. Hemkens LG, Grouven U, Bender R, Günster C, Gutschmidt S, Selke GW, et al. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 2009;52:1732-44.
  255. 255. Currie CJ, Poole CD, Gale EAM. The influence of glucose lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009;52:1766-77.
  256. 256. Mianowska B, Szadkowska A, Czerniawska E, Pietrzak I, Bodalski J. Insulin glargine improves fasting blood glucose levels in prepubertal children with unsatisfactorily controlled type 1 diabetes. Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw 2007;13(4):189-93.
  257. 257. Hassan K, Rodriguez LM, Johnson SE, Tadlock S, Heptulla RA. A randomized, controlled trial comparing twice-a-day unsulin glargine mixed with rapid-acting insulin analogs versus standard neutral protamine Hagedorn (NPH) therapy in newly diagnosed type 1 diabetes. Pediatrics 2008;121(3):e466-72.
  258. 258. Schober E, Schoenle E, Van Dyk J, Wernicke-Panten K. Comparative trial between insulin glargine and NPH insulin in children and adolescents with type 1 diabetes mellitus. J Pediatr Endocrinol Metab 2002;15(4):369-76.
  259. 259. Karges B, Kapellen T, Neu A, Hofer SE, Rohrer T, Rosenbauer J, et al. Long-acting insulin analogs and the risk of diabetic ketoacidosis in children and adolescents with type 1 diabetes: a prospective study of 10,682 patients from 271 institutions. Diabetes Care 2010 May;33(5):1031-3.
  260. 260. Robertson KJ, Schoenle E, Gucev Z, Mordhorst L, Gall MA, Ludvigsson J. Insulin determir compared with NPH insulin in children and adolescents with type 1 diabetes. Diabet Med 2007;24(1):27-34.
  261. 261. Pieber TR, Treichel HC, Hompesch B, Philotheou A, Mordhorst L, Gall MA, et al. Comparison of insulin determir and insulin glargine in subjects with type 1 diabetes using intensive insulin theraphy. Diabet Med 2007;24(6):635-42.
  262. 262. Heller S, Koenen C, Bode B. Comparison of insulin detemir and insulin glargine in a basalbolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferiority trial. Clin Ther 2009 Oct;31(10):2086-97.
  263. 263. Porcellati F, Rossetti P, Busciantella NR, Marzotti S, Lucidi P, Luzio S, et al. Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes: a double-blind, randomized, crossover study. Diabetes Care 2007 Oct;30(10):2447-52.
  264. 264. Cummins E, Royle P, Snaith A, Greene A, Robertson L, McIntyre L, et al. Clinical effectiveness and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes: systematic review and economic evaluation. Health Technol Assess 2010 Feb;14(11):iii-xvi, 1.
  265. 265. Fatourechi MM, Kudva YC, Murad MH, Elamin MB, Tabini CC, Montori VM. Hypoglycemia with intensive insulin therapy: a systematic review and meta-analyses of randomized trials of continuous subcutaneous insulin infusion versus multiple daily injections. J Clin Endocrinol Metab 2009;94(3):729-40.
  266. 266. Misso ML, Egberts KJ, Page M, O’Connor D, Shaw J. Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus. Cochrane Database Syst Rev 2010;(1):CD005103.
  267. 267. Bruttomesso D, Crazzolara D, Maran A, Costa S, Dal Pos M, Girelli A, et al. In Type 1 diabetic patients with good glycaemic control, blood glucose variability is lower during continuous subcutaneous insulin infusion than during multiple daily injections with insulin glargine. Diabet Med 2008;25(3):326-32.
  268. 268. DeVries JH, Snoek FJ, Kostense PJ, Masurel N, Heine RJ. A randomised trial of continuous subcutaneous insulin infusion and intensive injection therapy in type 1 diabetes for patients with longstanding poor glycemic control. Diabetes Care 2002;25:2074-80.
  269. 269. Hanaire-Broutin H, Melki V, Bessieres-Lacombe S, Tauber JP. Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens using insulin lispro in type 1 diabetic patients on intensified treatment: a randomized study. The Study Group for the Development of Pump Therapy in Diabetes. Diabetes Care 2000 Sep;23(9):1232-5.
  270. 270. Home PD, Capaldo B, Burrin JM, Worth R, Alberti KG. A crossover comparison of continuous subcutaneous insulin infusion (CSII) against multiple insulin injections in insulin-dependent diabetic subjects: improved control with CSII. Diabetes Care 1982 Sep;5(5):466-71.
  271. 271. Hoogma RP, Hammond PJ, Gomis R, et al. Comparison of the effects of continuous subcutaneous insulin infusion (CSII) and NPH-based multiple daily insulin injections (MDI) on glycaemic control and quality of life: results of the 5-nations trial. Diab Med 2005;23:141-7.
  272. 272. Lepore G, Dodesini AR, Nosari I, Trevisan R. Both continuous subcutaneous insulin infusion and a multiple daily insulin injection regimen with glargine as basal insulin are equally better than traditional multiple daily insulin injection treatment. Diabetes Care 2003 Apr;26(4):1321-2.
  273. 273. Nathan DM, Lou P, Avruch J. Intensive conventional and insulin pump therapies in adult type I diabetes. A crossover study. Ann Intern Med 1982 Jul;97(1):31-6.
  274. 274. Nosadini R, Velussi M, Fioretto P, et al. Frequency of hypoglycaemic and hyperglycaemicketotic episodes during convencional and subcutaneous continuous insulin infusion therapy in IDDM. Diabetes Nutr Metab 1988;1:289-96.
  275. 275. Dahl-Jorgensen K, Brinchmann-Hansen O, Hanssen KF, Sandvik L, Aagenaes O. Rapid tightening of blood glucose control leads to transient deterioration of retinopathy in insulin dependent diabetes mellitus: the Oslo study. Br Med J (Clin Res Ed) 1985 Mar 16;290(6471):811-5.
  276. 276. Dahl-Jorgensen K, Brinchmann-Hansen O, Hanssen KF, Ganes T, Kierulf P, Smeland E, et al. Effect of near normoglycaemia for two years on progression of early diabetic retinopathy, nephropathy, and neuropathy: the Oslo study. Br Med J (Clin Res Ed) 1986 Nov 8;293(6556):1195-9.
  277. 277. Brinchmann-Hansen O, hl-Jorgensen K, Sandvik L, Hanssen KF. Blood glucose concentrations and progression of diabetic retinopathy: the seven year results of the Oslo study. BMJ 1992 Jan 4;304(6818):19-22.
  278. 278. Saurbrey N, Arnold-Larsen S, Moller-Jensen B, Kuhl C. Comparison of continuous subcutaneous insulin infusion with multiple insulin injections using the NovoPen. Diabet Med 1988;5:150-3.
  279. 279. Schmitz A, Christiansen JS, Christensen CK, Hermansen K, Mogensen CE. Effect of pump versus pen treatment on glycaemic control and kidney function in long-term uncomplicated insulin-dependent diabetes mellitus (IDDM). Dan Med Bull 1989;36:176-8.
  280. 280. Tsui E, Barnie A, Ross S, Parkes R, Zinman B. Intensive insulin therapy with insulin lispro, a randomised trial of continuous subcutaneous insulin infusion versus multiple daily insulin injection. Diabetes Care 2001;24:1722-7.
  281. 281. Torres I, Ortego J, Valencia I, Garcia-Palacios MV, guilar-Diosdado M. Benefits of continuous subcutaneous insulin infusion in type 1 diabetes previously treated with multiple daily injections with once-daily glargine and pre-meal analogues. Exp Clin Endocrinol Diabetes 2009 Sep;117(8):378-85.
  282. 282. Bergenstal RM, Tamborlane WV, Ahmann A, Buse JB, Dailey G, Davis SN, et al. Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med 2010 Jul 22;363(4):311-20.
  283. 283. Bolli GB, Kerr D, Thomas R, Torlone E, Sola-Gazagnes A, Vitacolonna E, et al. Comparison of a multiple daily insulin injection regimen (basal once-daily glargine plus mealtime lispro) and continuous subcutaneous insulin infusion (lispro) in type 1 diabetes: a randomized open parallel multicenter study. Diabetes Care 2009 Jul;32(7):1170-6.
  284. 284. Doyle EA, Weinzimer SA, Steffen AT, Ahern JA, Vincent M, Tamborlane WV. A randomized, prospective trial comparing the efficacy of continuous subcutaneous insulin infusion with multiple daily injections using insulin glargine. Diabetes Care 2004;27:1554-8.
  285. 285. Schottenfeld-Naor Y, Galatzer A, Karp M, Josefsberg Z, Laron Z. Comparison of metabolic and psychological parameters during continuous subcutaneous insulin infusion and intensified conventional insulin treatment in type I diabetic patients. Isr J Med Sci 1985;21:822-8.
  286. 286. Ziegler D, Dannehl K, Koschinsky T, Toeller M, Gries FA. Comparison of continuous subcutaneous insulin infusion and intensified conventional therapy in the treatment of type I diabetes: a two-year randomized study. Diabetes Nutr Metab 1990;3:203-13.
  287. 287. Hoogma RP SD. Safety of insulin glulisine when given by continuous subcutaneous infusion using an external pump in patients with type 1 diabetes. Horm Metab Res 2006;38(6):429-33.
  288. 288. Barnard KD, Lloyd CE, Skinner TC. Systematic literature review: quality of life associated with insulin pump use in Type 1 diabetes. Diabet Med 2007;24(6):607-17.
  289. 289. Thomas RM, Aldibbiat A, Griffin W, Cox MA, Leech NJ, Shaw JA. A randomized pilot study in Type 1 diabetes complicated by severe hypoglycaemia, comparing rigorous hypoglycaemia avoidance with insulin analogue therapy, CSII or education alone. Diabet Med 2007;24(7): 778-83.
  290. 290. Conget I, Serrano D, Rodríguez JM, Levy I, Castell C, Roze S. Análisis coste-utilidad de las bombas de insulina frente a múltiples dosis diarias en pacientes con diabetes Mellitus tipo 1 en España. Rev Esp Salud pública 2006;80(6):679-95.
  291. 291. Pankowska E, Blazik M, Dziechciarz P, Szypowska A, Szajewska H. Continuous subcutaneous insulin infusion vs. multiple daily injections in children with type 1 diabetes: a systematic review and meta-analysis of randomized control trials. Pediatr Diabetes 2009 Feb;10(1):52-8.
  292. 292. De Beaufort CE, Houtzagers CM, Bruining GJ, Aarsen RS, Den Boer NC, Grose WF, et al. Continuous subcutaneous insulina infusion (CSII) versus conventional injection therapy in newly diagnosed diabetic children: two-year follow-up of a randomized, prospective trial. Diabet Med 1989;6:766-71.
  293. 293. Perlman K, Ehrlich RM, Filler RM, Albisser AM. Sustained normoglycemia in newly diagnosed type I diabetic subjects. Short-term effects and one-year follow-up. Diabetes 1984;33:995-1001.
  294. 294. Edelmann E, Walter H, Biermann E, Schleicher E, Bachmann W, Mehnert H. Sustained normoglycemia and remission phase in newly diagnosed type I diabetic subjects. Comparison between continuous subcutaneous insulin infusion and conventional therapy during a one year follow-up. Horm Metab Res 1987;19:419-21.
  295. 295. Opipari-Arrigan L, Fredericks EM, Burkhart N, Dale L, Hodge M, Foster C. Continuous subcutaneous insulin infusion benefits quality of life in preschool-age children with type 1 diabetes mellitus. Pediatr Diabetes 2007;8(6):377-83.
  296. 296. Wilson DM, Buckingham BA, Kunselman EL, Sullivan MM, Paguntalan HU, Gitelman SE. A two-center randomized controlled feasibility trial of insulin pump therapy in young children with diabetes. Diabetes Care 2005;28:15-9.
  297. 297. Cohen D, Weintrob N, Benzaquen H, Galatzer A, Fayman G, Phillip M. Continuous subcutaneous insulin infusion versus multiple daily injections in adolescents with type I diabetes mellitus: a randomized open crossover trial. J Pediatr Endocrinol Metab 2003 Sep;16(7):1047-50.
  298. 298. Meschi F, Beccaria L, Vanini R, Szulc M, Chiumello G. Short-term subcutaneous insulin infusion in diabetic children. Comparison with three daily insulin injections. Acta Diabetol Lat 1982 Oct;19(4):371-5.
  299. 299. Nuboer R, Borsboom GJ, Zoethout JA, Koot HM, Bruining J. Effects of insulin pump vs. injection treatment on quality of life and impact of disease in children with type 1 diabetes mellitus in a randomized, prospective comparison. Pediatr Diabetes 2008 Jul 28;9(4 Pt 1):291-6.
  300. 300. Pozzilli P, Crino A, Schiaffini R, Manfrini S, Fioriti E, Coppolino G, et al. A 2-year pilot trial of continuous subcutaneous insulin infusion versus intensive insulin therapy in patients with newly diagnosed type 1 diabetes (IMDIAB 8). Diabetes Technol Ther 2003;5(6):965-74.
  301. 301. Skogsberg L, Fors H, Hanas R, Chaplin JE, Lindman E, Skogsberg J. Improved treatment satisfaction but no difference in metabolic control when using continuous subcutaneous insulin infusion vs. multiple daily injections in children at onset of type 1 diabetes mellitus. Pediatr Diabetes 2008;9(5):472-9.
  302. 302. Weintrob N, Schechter A, Benzaquen H, Shalitin S, Lilos P, Galatzer A, et al. Glycemic patterns detected by continuous subcutaneous glucose sensing in children and adolescents with type 1 diabetes mellitus treated by multiple daily injections vs continuous subcutaneous insulin infusion. Arch Pediatr Adolesc Med 2004 Jul;158(7):677-84.
  303. 303. Schiffrin A, Desrosiers M, Moffat M, Belmonte MM. Feasibility of strict diabetes control in insulin-dependent diabetic adolescents. J Pediatr 1983;103:522-7.
  304. 304. Weintrob N, Benzaquen H, Galatzer A, Shalitin S, Lazar L, Fayman G, et al. Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens in children with type 1 diabetes: a randomized open crossover trial. Pediatrics 2003;112:559-64.
  305. 305. Fox LA, Buckloh LM, Smith SD, Wysocki T, Mauras N. A randomised controlled trial of insulin pump therapy in young children with type 1 diabetes. Diabetes Care 2005;28:1277-81.
  306. 306. Farrar D, Tufnell DJ, West J. Continuous subcutaneous insulin infusion versus multiple daily injections of insulin for pregnant women with diabetes. Cochrane Databases Syst Rev 2007;18(3).
  307. 307. Nosari I, Maglio ML, Lepore G, Cortinovis F, Pagani G. Is continuous subcutaneous insulin infusion more effective than intensive convencional insulin therapy in the treatment of pregnant diabetic women? Diabetes, Nutrition & Metabolism - Clinical & Experimental 1993;6:33-7.
  308. 308. Carta Q, Meriggi E, Trossarelli GF, Catella G, Dal Molin V, Menato G, et al. Continuous subcutaneous insulin infusion versus intensive convencional insulin therapy in type I and type II diabetic pregnancy. Diabete et Metabolisme 1986;12:121-9.
  309. 309. Murray DP, Keenan P, Gayer E, Salmon P, Tomkin GH, Drury MI, et al. A randomized trial of the efficacy and acceptability of a pen injector. Diabet Med 1988 Nov;5(8):750-4.
  310. 310. Kolendorf K, Beck-Nielsen H, Oxenboll B. Clinical experience with NovoPen II and insulin Protaphane HM Penfill. Postgrad Med J 1988;64 Suppl 3:14-6.
  311. 311. Jorgensen JO, Flyvbjerg A, Jorgensen JT, Sorensen HH, Johansen BR, Christiansen JS. NPH insulin administration by means of a pen injector. Diabet Med 1988 Sep;5(6):574-6.
  312. 312. Chen HS, Hwu CM, Kwok CF, Yang HJ, Shih KC, Lin BJ, et al. Clinical response and patient acceptance of a prefilled, disposable insulin pen injector for insulin-treated diabetes. Zhonghua Yi Xue Za Zhi (Taipei) 1999 Jul;62(7):455-60.
  313. 313. Engström LHK. Insulin pen for administration of isophane insulin. Pract Diab Int 1990;7(4):162-4.
  314. 314. Korytkowski M, Bell D, Jacobsen C, Suwannasari R. A multicenter, randomized, open-label, comparative, two-period crossover trial of preference, efficacy, and safety profiles of a prefilled, disposable pen and conventional vial/syringe for insulin injection in patients with type 1 or 2 diabetes mellitus. Clin Ther 2003 Nov;25(11):2836-48.
  315. 315. Shelmet J, Schwartz S, Cappleman J, Peterson G, Skovlund S, Lytzen L, et al. Preference and resource utilization in elderly patients: InnoLet versus vial/syringe. Diabetes Res Clin Pract 2004 Jan;63(1):27-35.
  316. 316. Stockl K, Ory C, Vanderplas A, Nicklasson L, Lyness W, Cobden D, et al. An evaluation of patient preference for an alternative insulin delivery system compared to standard vial and syringe. Curr Med Res Opin 2007 Jan;23(1):133-46.
  317. 317. Molife C, Lee LJ, Shi L, Sawhney M, Lenox SM. Assessment of patient-reported outcomes of insulin pen devices versus conventional vial and syringe. Diabetes Technol Ther 2009 Aug;11(8):529-38.
  318. 318. Asche CV, Shane-McWhorter L, Raparla S. Health economics and compliance of vials/syringes versus pen devices: a review of the evidence. Diabetes Technol Ther 2010 Jun;12 Suppl 1:S101-S108.
  319. 319. Costa B, Estopa A, Borras J, Sabate A. Diabetes and pharmacoeconomics. Efficiency of insulin injection methods available in Spain. Aten Primaria 1995 Oct 31;16(7):391-6.
  320. 320. Perry LJ. A multicentre study of the acceptability and convenience of a disposable pen injection device (preloaded pen) in children and adolescents. Novo Nordisk [unpublished] 1993.
  321. 321. Arslanoglu I, Saka N, Bundak R, Gunoz H, Darendeliler F. A comparison of the use of premixed insulins in pen-injectors with conventional patient-mixed insulin treatment in children and adolescents with IDDM. Is there a decreased risk of night hypoglycemia? J Pediatr Endocrinol Metab 2000 Mar;13(3):313-8.
  322. 322. Valk NK, Cerny G, Sieber J, Lytzen L, Berg B. Efficacy and safety performance of the Innovo insulin doser. Diabetes Technol Ther 2004 Feb;6(1):53-8.
  323. 323. Vidal M, Colungo C, Jansà M. Update on insulin administration techniques and devices (I). Av Diabetol 2008;24 (2):175-9.
  324. 324. Henriksen JE, Djurhuus MS, Vaag A, Thye-Ronn P, Knudsen D, Hother-Nielsen O, et al. Impact of injection sites for soluble insulin on glycaemic control in type 1 (insulin-dependent) diabetic patients treated with a multiple insulin injection regimen. Diabetologia 1993 Aug;36(8):752-8.
  325. 325. Koivisto VA, Felig P. Alterations in insulin absorption and in blood glucose control associated with varying insulin injection sites in diabetic patients. Ann Intern Med 1980 Jan;92(1):59-61.
  326. 326. Bantle JP, Weber MS, Rao SM, Chattopadhyay MK, Robertson RP. Rotation of the anatomic regions used for insulin injections and day-to-day variability of plasma glucose in type I diabetic subjects. JAMA 1990 Apr 4;263(13):1802-6.
  327. 327. Bantle JP, Neal L, Frankamp LM. Effects of the anatomical region used for insulin injections on glycemia in type I diabetes subjects. Diabetes Care 1993 Dec;16(12):1592-7.
  328. 328. Frid A, Hirsch L, Gaspar R, Hicks D, Kreugel G, Liersch J, et al. New injection recommendations for patients with diabetes. Diabetes Metab 2010 Sep;36 Suppl 2:S3-18.
  329. 329. Frid A, Hirsch L, Gaspar R, Hicks D, Kreugel G, Liersch J, et al. The Third Injection Technique Workshop in Athens (TITAN). Diabetes Metab 2010 Sep;36 Suppl 2:S19-S29.
  330. 330. Strauss K. Insulin injection techniques. Report from the 1st International Insulin Injection Technique Workshop, Strasbourg, FranceGÇöJune 1997. Pract Diab Int 1998;15(6):181-4.
  331. 331. Davis ED, Chesnaky P. Site rotation: an old practice gains new currency in light of todays research. Diabetes Forecast 1992;3:54-6.
  332. 332. Frid A, Linden B. Where do lean diabetics inject their insulin? A study using computed tomography. Br Med J (Clin Res Ed) 1986 Jun 21;292(6536):1638.
  333. 333. Engstrom L, Bergman A. A new injection technique for insulin treatment, simpler to use and as effective? Scand J Caring Sci 1993;7(1):57-9.
  334. 334. Birkebaek NH, Solvig J, Hansen B, Jorgensen C, Smedegaard J, Christiansen JS. A 4-mm needle reduces the risk of intramuscular injections without increasing backflow to skin surface in lean diabetic children and adults. Diabetes Care 2008 Sep;31(9):e65.
  335. 335. Gibney MA, Arce CH, Byron KJ, Hirsch LJ. Skin and subcutaneous adipose layer thickness in adults with diabetes at sites used for insulin injections: implications for needle length recommendations. Curr Med Res Opin 2010 Jun;26(6):1519-30.
  336. 336. Hofman PL, Lawton SA, Peart JM, Holt JA, Jefferies CA, Robinson E, et al. An angled insertion technique using 6-mm needles markedly reduces the risk of intramuscular injections in children and adolescents. Diabet Med 2007 Dec;24(12):1400-5.
  337. 337. Fleming DR, Jacober SJ, Vandenberg MA, Fitzgerald JT, Grunberger G. The safety of injecting insulin through clothing. Diabetes Care 1997 Mar;20(3):244-7.
  338. 338. Schwartz S, Hassman D, Shelmet J, Sievers R, Weinstein R, Liang J, et al. A multicenter, open-label, randomized, two-period crossover trial comparing glycemic control, satisfaction, and preference achieved with a 31 gauge x 6 mm needle versus a 29 gauge x 12.7 mm needle in obese patients with diabetes mellitus. Clin Ther 2004 Oct;26(10):1663-78.
  339. 339. Hirsch LJ, Gibney MA, Albanese J, Qu S, Kassler-Taub K, Klaff LJ, et al. Comparative glycemic control, safety and patient ratings for a new 4 mm x 32G insulin pen needle in adults with diabetes. Curr Med Res Opin 2010 Jun;26(6):1531-41.
  340. 340. Kreugel G, Beijer HJM, Kerstens MN, Ter Maaten JC, Sluiter WJ, Boot BS. Influence of needle size for SC insulin administration on metabolic control and patient acceptance. Europ Diab Nursing 2007 2007;4:1-5.
  341. 341. Ross SA, Jamal R, Leiter LA, Josse RG, Parkes JL, Qu S, et al. Evaluation of 8 mm insulin pen needles in people with type 1 and type 2 diabetes. Pract Diab Int 1999;16(5):145-8.
  342. 342. Tubiana-Rufi N, Belarbi N, Du Pasquier-Fediaevsky L, Polak M, Kakou B, Leridon L, et al. Short needles (8 mm) reduce the risk of intramuscular injections in children with type 1 diabetes. Diabetes Care 1999 Oct;22(10):1621-5.
  343. 343. Hamilton J, Cummings E, Zdravkovic V, Finegood D, Daneman D. Metformin as an adjunct therapy in adolescents with type 1 diabetes and insulin resistance: a randomized controlled trial. Diabetes Care 2003 Jan;26(1):138-43.
  344. 344. Sarnblad S, Kroon M, Aman J. Metformin as additional therapy in adolescents with poorly controlled type 1 diabetes: randomised placebo-controlled trial with aspects on insulin sensitivity. Eur J Endocrinol 2003 Oct;149(4):323-9.
  345. 345. Vella S, Buetow L, Royle P, Livingstone S, Colhoun HM, Petrie JR. The use of metformin in type 1 diabetes: a systematic review of efficacy. Diabetologia 2010 May;53(5):809-20.
  346. 346. Abdelghaffar S, Attia AM. Metformin added to insulin therapy for type 1 diabetes mellitus in adolescents. Cochrane Database Syst Rev 2009;(1):CD006691.
  347. 347. Cohen DJ, St ML, Christensen LL, Bloom RD, Sung RS. Kidney and pancreas transplantation in the United States, 1995-2004. Am J Transplant 2006;6(5 Pt 2):1153-69.
  348. 348. Venstrom JM, McBride MA, Rother KI, Hirshberg B, Orchard TJ, Harlan DM. Survival after pancreas transplantation in patients with diabetes and preserved kidney function. JAMA 2003 Dec 3;290(21):2817-23.
  349. 349. Nathan DM. Isolated pancreas transplantation for type 1 diabetes: a doctor’s dilemma. JAMA 2003 Dec 3;290(21):2861-3.
  350. 350. Gruessner RW, Sutherland DE, Gruessner AC. Mortality assessment for pancreas transplants. Am J Transplant 2004 Dec;4(12):2018-26.
  351. 351. Pozza G, Traeger J, Dubernard JM, Secchi A, Pontiroli AE, Bosi E, et al. Endocrine responses of type 1 (insulin-dependent) diabetic patients following successful pancreas transplantation. Diabetologia 1983 Apr;24(4):244-8.
  352. 352. Katz H, Homan M, Velosa J, Robertson P, Rizza R. Effects of pancreas transplantation on postprandial glucose metabolism. N Engl J Med 1991 Oct 31;325(18):1278-83.
  353. 353. Diem P, Abid M, Redmon JB, Sutherland DE, Robertson RP. Systemic venous drainage of pancreas allografts as independent cause of hyperinsulinemia in type I diabetic recipients. Diabetes 1990 May;39(5):534-40.
  354. 354. Osei K, Henry ML, O’Dorisio TM, Tesi RJ, Sommer BG, Ferguson RM. Physiological and pharmacological stimulation of pancreatic islet hormone secretion in type I diabetic pancreas allograft recipients. Diabetes 1990 Oct;39(10):1235-42.
  355. 355. Elahi D, Clark BA, oon-Dyke M, Wong G, Brown R, Shapiro M, et al. Islet cell responses to glucose in human transplanted pancreas. Am J Physiol 1991 Dec;261(6 Pt 1):E800-E808.
  356. 356. Robertson RP, Diem P, Sutherland DE. Time-related, cross-sectional and prospective followup of pancreatic endocrine function after pancreas allograft transplantation in type 1 (insulindependent) diabetic patients. Diabetologia 1991 Aug;34 Suppl 1:S57-S60.
  357. 357. Landgraf R, Nusser J, Riepl RL, Fiedler F, Illner WD, Abendroth D, et al. Metabolic and hormonal studies of type 1 (insulin-dependent) diabetic patients after successful pancreas and kidney transplantation. Diabetologia 1991 Aug;34 Suppl 1:S61-S67.
  358. 358. Secchi A, Dubernard JM, La RE, LeFrancois N, Melandri M, Martin X, et al. Endocrinometabolic effects of whole versus segmental pancreas allotransplantation in diabetic patients--a two-year follow-up. Transplantation 1991 Mar;51(3):625-9.
  359. 359. Barrou Z, Seaquist ER, Robertson RP. Pancreas transplantation in diabetic humans normalizes hepatic glucose production during hypoglycemia. Diabetes 1994 May;43(5):661-6.
  360. 360. Kendall DM, Rooney DP, Smets YF, Salazar BL, Robertson RP. Pancreas transplantation restores epinephrine response and symptom recognition during hypoglycemia in patients with long-standing type I diabetes and autonomic neuropathy. Diabetes 1997 Feb;46(2):249-57.
  361. 361. Cottrell DA, Henry ML, O’Dorisio TM, Tesi RJ, Ferguson RM, Osei K. Hypoglycemia after successful pancreas transplantation in type I diabetic patients. Diabetes Care 1991 Nov;14(11):1111-3.
  362. 362. Redmon JB, Teuscher AU, Robertson RP. Hypoglycemia after pancreas transplantation. Diabetes Care 1998 Nov;21(11):1944-50.
  363. 363. Robertson RP, Sutherland DE, Kendall DM, Teuscher AU, Gruessner RW, Gruessner A. Metabolic characterization of long-term successful pancreas transplants in type I diabetes. J Investig Med 1996 Dec;44(9):549-55.
  364. 364. Robertson RP. Pancreas and islet transplants for patients with diabetes: taking positions and making decisions. Endocr Pract 1999 Jan;5(1):24-8.
  365. 365. Bohman SO, Tyden G, Wilczek H, Lundgren G, Jaremko G, Gunnarsson R, et al. Prevention of kidney graft diabetic nephropathy by pancreas transplantation in man. Diabetes 1985 Mar;34(3):306-8.
  366. 366. Bilous RW, Mauer SM, Sutherland DE, Najarian JS, Goetz FC, Steffes MW. The effects of pancreas transplantation on the glomerular structure of renal allografts in patients with insulin- dependent diabetes. N Engl J Med 1989 Jul 13;321(2):80-5.
  367. 367. Fioretto P, Steffes MW, Sutherland DE, Goetz FC, Mauer M. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 1998 Jul 9;339(2):69-75.
  368. 368. Navarro X, Kennedy WR, Loewenson RB, Sutherland DE. Influence of pancreas transplantation on cardiorespiratory reflexes, nerve conduction, and mortality in diabetes mellitus. Diabetes 1990 Jul;39(7):802-6.
  369. 369. Navarro X, Kennedy WR, Sutherland DE. Autonomic neuropathy and survival in diabetes mellitus: effects of pancreas transplantation. Diabetologia 1991 Aug;34 Suppl 1:S108-S112.
  370. 370. Navarro X, Sutherland DE, Kennedy WR. Long-term effects of pancreatic transplantation on diabetic neuropathy. Ann Neurol 1997 Nov;42(5):727-36.
  371. 371. Aridge D, Reese J, Niehoff M, Carney K, Lindsey L, Chun HS, et al. Effect of successful renal and segmental pancreatic transplantation on peripheral and autonomic neuropathy. Transplant Proc 1991 Feb;23(1 Pt 2):1670-1.
  372. 372. Allen RD, Al-Harbi IS, Morris JG, Clouston PD, O’Connell PJ, Chapman JR, et al. Diabetic neuropathy after pancreas transplantation: determinants of recovery. Transplantation 1997 Mar 27;63(6):830-8.
  373. 373. Gaber AO, Cardoso S, Pearson S, Abell T, Gaber L, Hathaway D, et al. Improvement in autonomic function following combined pancreas-kidney transplantation. Transplant Proc 1991 Feb;23(1 Pt 2):1660-2.
  374. 374. Fiorina P, La RE, Venturini M, Minicucci F, Fermo I, Paroni R, et al. Effects of kidney-pancreas transplantation on atherosclerotic risk factors and endothelial function in patients with uremia and type 1 diabetes. Diabetes 2001 Mar;50(3):496-501.
  375. 375. Piper M, Seidenfeld J, Aronson N. Islet transplantation in patients with type 1 diabetes mellitus. Evid Rep Technol Assess (Summ ) 2004 Jul;(98):1-6.
  376. 376. ECRI. Islet cell transplantation for the treatment of type 1 diabetes. Plymouth Meeting, PA: ECRI 2005; 72 2005.
  377. 377. Guo B, Harstall C, Corabian P. Islet Cell Transplantation for the Treatment of Non-uremic Type 1 Diabetic Patients with Severe Hypoglycemia. Alberta Heritage Foundation for Medical Researc HTA 31 Health Technology Assessment 2003 Apr.
  378. 378. Hirshberg B, Rother KI, Digon BJ, III, Lee J, Gaglia JL, Hines K, et al. Benefits and risks of solitary islet transplantation for type 1 diabetes using steroid-sparing immunosuppression: the National Institutes of Health experience. Diabetes Care 2003 Dec;26(12):3288-95.
  379. 379. Hering BJ, Kandaswamy R, Ansite JD, Eckman PM, Nakano M, Sawada T, et al. Single-donor, marginal-dose islet transplantation in patients with type 1 diabetes. JAMA 2005 Feb 16;293(7):830-5.
  380. 380. Shapiro AM, Ricordi C, Hering BJ, Auchincloss H, Lindblad R, Robertson RP, et al. International trial of the Edmonton protocol for islet transplantation. N Engl J Med 2006 Sep 28;355(13):1318-30.
  381. 381. Ryan EA, Paty BW, Senior PA, Bigam D, Alfadhli E, Kneteman NM, et al. Five-year followup after clinical islet transplantation. Diabetes 2005 Jul;54(7):2060-9.
  382. 382. Froud T, Ricordi C, Baidal DA, Hafiz MM, Ponte G, Cure P, et al. Islet transplantation in type 1 diabetes mellitus using cultured islets and steroid-free immunosuppression: Miami experience. Am J Transplant 2005 Aug;5(8):2037-46.
  383. 383. Hering BJ, Kandaswamy R, Harmon JV, Ansite JD, Clemmings SM, Sakai T, et al. Transplantation of cultured islets from two-layer preserved pancreases in type 1 diabetes with anti- CD3 antibody. Am J Transplant 2004 Mar;4(3):390-401.
  384. 384. Lee TC, Barshes NR, O’Mahony CA, Nguyen L, Brunicardi FC, Ricordi C, et al. The effect of pancreatic islet transplantation on progression of diabetic retinopathy and neuropathy. Transplant Proc 2005 Jun;37(5):2263-5.
  385. 385. Maffi P, Bertuzzi F, De TF, Magistretti P, Nano R, Fiorina P, et al. Kidney function after islet transplant alone in type 1 diabetes: impact of immunosuppressive therapy on progression of diabetic nephropathy. Diabetes Care 2007 May;30(5):1150-5.
  386. 386. Keymeulen B, Gillard P, Mathieu C, Movahedi B, Maleux G, Delvaux G, et al. Correlation between beta cell mass and glycemic control in type 1 diabetic recipients of islet cell graft. Proc Natl Acad Sci U S A 2006 Nov 14;103(46):17444-9.
  387. 387. Badet L, Benhamou PY, Wojtusciszyn A, Baertschiger R, Milliat-Guittard L, Kessler L, et al. Expectations and strategies regarding islet transplantation: metabolic data from the GRAGIL 2 trial. Transplantation 2007 Jul 15;84(1):89-96.
  388. 388. O’Connell PJ, Hawthorne WJ, Holmes-Walker DJ, Nankivell BJ, Gunton JE, Patel AT, et al. Clinical islet transplantation in type 1 diabetes mellitus: results of Australia’s first trial. Med J Aust 2006 Mar 6;184(5):221-5.
  389. 389. Shapiro AM, Lakey JR, Ryan EA, Korbutt GS, Toth E, Warnock GL, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000 Jul 27;343(4):230-8.
  390. 390. Barshes NR, Vanatta JM, Mote A, Lee TC, Schock AP, Balkrishnan R, et al. Health-related quality of life after pancreatic islet transplantation: a longitudinal study. Transplantation 2005 Jun 27;79(12):1727-30.
  391. 391. Fung MA, Warnock GL, Ao Z, Keown P, Meloche M, Shapiro RJ, et al. The effect of medical therapy and islet cell transplantation on diabetic nephropathy: an interim report. Transplantation 2007 Jul 15;84(1):17-22.
  392. 392. Frank A, Deng S, Huang X, Velidedeoglu E, Bae YS, Liu C, et al. Transplantation for type I diabetes: comparison of vascularized whole-organ pancreas with isolated pancreatic islets. Ann Surg 2004 Oct;240(4):631-40.
  393. 393. Furnary AP, Zerr KJ, Grunkemeier GL, Starr A. Continuous intravenous insulin infusion reduces the incidence of deep sternal wound infection in diabetic patients after cardiac surgical procedures. Ann Thorac Surg 1999;67(2):352-60.
  394. 394. Christiansen CL, Schurizek BA, Malling B, Knudsen L, Alberti KG, Hermansen K. Insulin treatment of the insulin-dependent diabetic patient undergoing minor surgery. Continuous intravenous infusion compared with subcutaneous administration. Anaesth 1988;43(7):533-7.
  395. 395. Pezzarossa A, Taddei F, Cimicchi MC, Rossini E, Contini S, Bonora E, et al. Perioperative management of diabetic subjects. Subcutaneous versus intravenous insulin administration during glucose-potassium infusion. Diabetes Care 1988;11(1):52-8.
  396. 396. Simmons D, Morton K, Laughton SJ, Scott DJ. A comparison of two intravenous insulin regimens among surgical patients with insulin-dependent diabetes mellitus. Diabetes Educ 1994;20(5):422-7.
  397. 397. Furnary AP, Gao G, Grunkemeier GL, Wu Y, ZAerr KL, Bookin SO, et al. Continuous insulin infusion reduces mortality in patients with diabetes under-going coronary artery bypass grafting. J Thorac Cardiovasc Surg 2003;125:1007-21.
  398. 398. Gandhi GY, Murad MH, Flynn DN, Erwin PJ, Cavalcante AB, Bay NH, et al. Effect of perioperative insulin infusion on surgical morbidity and mortality: systematic review and metaanalysis of randomized trials.7. Mayo Clin Proc 2008;83(4):418-30.
  399. 399. Malmberg K, Ryden L, Efendic S, et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol 1995;26:57-65.

Última actualización: noviembre 2012

Logo del Ministerio de Ciencia e Innovación Logo del Ministerio de Sanidad y Política Social Logo del Plan de Calidad para el Sistema Nacional de SaludAgencia de Evaluación de Tecnologías Sanitarias del País Vasco (OSTEBA)

 

Copyright | Ayuda | Mapa